Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1971 1
1972 1
1974 1
1975 1
1976 3
1977 4
1978 1
1979 1
1980 2
1981 3
1982 2
1983 4
1984 5
1985 2
1986 3
1987 7
1988 20
1989 14
1990 13
1991 14
1992 14
1993 28
1994 34
1995 28
1996 18
1997 37
1998 24
1999 35
2000 38
2001 38
2002 35
2003 29
2004 40
2005 44
2006 35
2007 29
2008 36
2009 28
2010 44
2011 32
2012 28
2013 44
2014 53
2015 60
2016 51
2017 55
2018 59
2019 62
2020 71
2021 70
2022 59
2023 67
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

1,351 results

Results by year

Filters applied: . Clear all
Page 1
Advances in systemic therapy for non-small cell lung cancer.
Miller M, Hanna N. Miller M, et al. BMJ. 2021 Nov 9;375:n2363. doi: 10.1136/bmj.n2363. BMJ. 2021. PMID: 34753715 Review.
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patient …
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over …
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ Jr, Choy H. Bradley JD, et al. J Clin Oncol. 2020 Mar 1;38(7):706-714. doi: 10.1200/JCO.19.01162. Epub 2019 Dec 16. J Clin Oncol. 2020. PMID: 31841363 Free PMC article. Clinical Trial.
PURPOSE: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC). ...For comparison …
PURPOSE: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determi …
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H. Bradley JD, et al. Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16. Lancet Oncol. 2015. PMID: 25601342 Free PMC article. Clinical Trial.
BACKGROUND: We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small …
BACKGROUND: We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemothe …
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S. De Ruysscher D, et al. Clin Lung Cancer. 2022 May;23(3):e264-e268. doi: 10.1016/j.cllc.2021.07.005. Epub 2021 Jul 19. Clin Lung Cancer. 2022. PMID: 34489161 Free article. Clinical Trial.
INTRODUCTION: The 5 year survival rate for patients with locally advanced non-small-cell lung cancer (NSCLC) not amenable for definitive resection with historical standard-of-care concurrent chemoradiotherapy (cCRT) ranges from 15% …
INTRODUCTION: The 5 year survival rate for patients with locally advanced non-small-cell lung cancer ( …
Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.
Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD. Videtic GM, et al. Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084. doi: 10.1016/j.ijrobp.2018.11.051. Epub 2018 Dec 1. Int J Radiat Oncol Biol Phys. 2019. PMID: 30513377 Free PMC article. Clinical Trial.
PURPOSE: To present long-term results of RTOG 0915/NCCTG N0927, a randomized lung stereotactic body radiation therapy trial of 34 Gy in 1 fraction versus 48 Gy in 4 fractions. METHODS AND MATERIALS: This was a phase 2 multicenter study of patients with medica …
PURPOSE: To present long-term results of RTOG 0915/NCCTG N0927, a randomized lung stereotactic body radiation therapy t …
Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, Shi A, Jiang W, Xu Y, Zhou Z, Wang W, Chen D, Hui Z, Lv J, Zhang H, Feng Q, Xiao Z, Wang X, Liu L, Zhang T, Du L, Chen W, Shyr Y, Yin W, Li J, He J, Wang L. Liang J, et al. Ann Oncol. 2017 Apr 1;28(4):777-783. doi: 10.1093/annonc/mdx009. Ann Oncol. 2017. PMID: 28137739 Free article. Clinical Trial.
BACKGROUND: The optimal chemotherapy regimen administered currently with radiation in patients with stage III non-small cell lung cancer (NSCLC) remains unclear. ...CONCLUSION: EP might be superior to weekly PC in terms of OS in th …
BACKGROUND: The optimal chemotherapy regimen administered currently with radiation in patients with stage III non-small …
Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Swaminath A, Wierzbicki M, Parpia S, Wright JR, Tsakiridis TK, Okawara GS, Kundapur V, Bujold A, Ahmed N, Hirmiz K, Kurien E, Filion E, Gabos Z, Faria S, Louie AV, Owen T, Wai E, Ramchandar K, Chan EK, Julian J, Cline K, Whelan TJ. Swaminath A, et al. Clin Lung Cancer. 2017 Mar;18(2):250-254. doi: 10.1016/j.cllc.2016.08.002. Epub 2016 Oct 3. Clin Lung Cancer. 2017. PMID: 27876603 Clinical Trial.
We describe a Canadian phase III randomized controlled trial of stereotactic body radiotherapy (SBRT) versus conventionally hypofractionated radiotherapy (CRT) for the treatment of stage I medically inoperable non-small-cell lun …
We describe a Canadian phase III randomized controlled trial of stereotactic body radiotherapy (SBRT) versus conventionally hy …
Radiation Therapy in Non-Small-Cell Lung Cancer.
Dohopolski M, Gottumukkala S, Gomez D, Iyengar P. Dohopolski M, et al. Cold Spring Harb Perspect Med. 2021 Oct 1;11(10):a037713. doi: 10.1101/cshperspect.a037713. Cold Spring Harb Perspect Med. 2021. PMID: 34127511 Free PMC article. Review.
The management of non-small-cell lung cancer (NSCLC) varies according to stage. Surgical resection is reserved for operable patients with early-stage NSCLC, while high-dose target radiation-stereotactic body radiation …
The management of non-small-cell lung cancer (NSCLC) varies according to stage. Surgical resection …
Radiotherapy and Immunotherapy Combinations for Lung Cancer.
Agrawal V, Benjamin KT, Ko EC. Agrawal V, et al. Curr Oncol Rep. 2020 Nov 19;23(1):4. doi: 10.1007/s11912-020-00993-w. Curr Oncol Rep. 2020. PMID: 33215306 Review.
PURPOSE OF REVIEW: Positive results from recent immunotherapy trials of non-small cell lung cancer (NSCLC) have coincided with a greater appreciation for the impact of radiation therapy (RT) on tumor immunity. Here, we summarize ke …
PURPOSE OF REVIEW: Positive results from recent immunotherapy trials of non-small cell lung cancer (NS …
Non-surgical Therapies for Early-stage Non-small Cell Lung Cancer: A Systematic Review.
Sultan S, Ullman K, Ester E, Melzer A, Anthony M, Kelly RF, Landsteiner A, Stampe C, Thiboutot J, Wilt TJ. Sultan S, et al. Washington (DC): Department of Veterans Affairs (US); 2023 Jun. Washington (DC): Department of Veterans Affairs (US); 2023 Jun. PMID: 37363959 Free Books & Documents. Review.
Lung cancer is the leading cause of cancer-related deaths in the United States (US). The majority of lung cancers are diagnosed at advanced stages but with the advent of lung cancer screening, the number of individuals diagnosed wi …
Lung cancer is the leading cause of cancer-related deaths in the United States (US). The majority of lung can …
1,351 results